ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

168
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
Refresh
21 Apr 2020 21:49

Hansoh Pharma Placement - Good Stock but Valuation and No Lack of Cash Makes It Appear Opportunistic

Hansoh Pharmaceutical (3692 HK) aims to raise up to US$450m to funds its R&D and general working capital requirements. The company was listed...

Logo
389 Views
Share
20 Apr 2020 20:39

Sino Biopharm (中国生物制药) Placement - Not a Big Deal, Still a Good Company but Relatively Expensive

A shareholder of Sino Biopharmaceutical (1177 HK) is looking to sell about US$297m worth of shares in an accelerated block trade.In this note, we...

Share
14 Apr 2020 14:04

Akesobio IPO: Valuation Insights

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
468 Views
Share
14 Apr 2020 13:47

Akesobio (康方生物) IPO: Expect near Zero Allocation

Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...

Logo
566 Views
Share
08 Apr 2020 19:50

Akesobio IPO Initiation: The Tough Get Going

Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...

Logo
460 Views
Share
x